Lourdes G. Weltzien - 15 Feb 2022 Form 4 Insider Report for MERIDIAN BIOSCIENCE INC

Role
EVP, Life Science
Signature
/s/ F. Mark Reuter as Attorney-in-Fact for Lourdes G. Weltzien
Issuer symbol
N/A
Transactions as of
15 Feb 2022
Net transactions value
-$221,537
Form type
4
Filing time
17 Feb 2022, 10:22:57 UTC
Previous filing
22 Dec 2021
Next filing
08 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIVO Common Stock Options Exercise $183,125 +12,500 +15% $14.65 95,548 15 Feb 2022 Direct
transaction VIVO Common Stock Options Exercise $107,250 +7,500 +7.8% $14.30 103,048 15 Feb 2022 Direct
transaction VIVO Common Stock Sale $511,912 -20,000 -19% $25.60 83,048 15 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIVO Stock Options (Right to Buy) Options Exercise $0 -12,500 -100% $0.000000* 0 15 Feb 2022 Common Stock 12,500 $14.65 Direct F2
transaction VIVO Stock Options (Right to Buy) Options Exercise $0 -7,500 -75% $0.000000 2,500 15 Feb 2022 Common Stock 7,500 $14.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $25.29 to $26.07. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
F2 These non-qualified options were awarded under the 2012 Stock Incentive Plan and cliff vested in full on November 15, 2021.
F3 These options were awarded under the 2012 Stock Incentive Plan and vest in four equal installments from the date of grant until fully vested on April 24, 2022.